Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20451492 | 0.91 | GPR84 (0.55) | GPR84FFAR1FFAR4 | |
| SCHEMBL19976382 | 0.91 | GPR84 (0.55) | GPR84FFAR1FFAR4 | |
| SCHEMBL851936 | 0.86 | — | — | |
| SCHEMBL1661341 | 0.82 | FFAR1 (0.54) | FFAR1FFAR4 | |
| SCHEMBL1661339 | 0.82 | FFAR1 (0.54) | FFAR1FFAR4 | |
| SCHEMBL28656099 | 0.79 | CNR2 (0.53) | CA2MAPK1GPR84FFAR1CA1 | |
| SCHEMBL1300172 | 0.77 | TAS1R3 (0.54) | CA2MAPK1CA1PLA2G2CCNR2 | |
| SCHEMBL12415210 | 0.77 | DNM1 (0.41) | CA2MAPK1CA1PLA2G2C | |
| SCHEMBL13879267 | 0.77 | TGFBR1 (0.44) | CA2MAPK1GPR84FFAR1CA1 | |
| SCHEMBL12415206 | 0.77 | ASAH1 (0.44) | CA2MAPK1GPR84CA1PLA2G2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4359006-A1 | ANTISENSE COMPOUNDS AND METHODS FOR TARGETING CUG REPEATS | Entrada Therapeutics, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| EP-4337263-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERFERON REGULATORY FACTOR-5 (IRF-5) ACTIVITY | Entrada Therapeutics, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-4337264-A1 | COMPOSITIONS AND METHODS FOR MODULATING TISSUE DISTRIBUTION OF INTRACELLULAR THERAPEUTICS | Entrada Therapeutics, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-4337261-A2 | COMPOSITIONS AND METHODS FOR MODULATING MRNA SPLICING | Entrada Therapeutics, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| WO-2022271818-A1 | ANTISENSE COMPOUNDS AND METHODS FOR TARGETING CUG REPEATS | ENTRADA THERAPEUTICS, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2021127650-A1 | COMPOSITIONS FOR DELIVERY OF ANTISENSE COMPOUNDS | ENTRADA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2011163121-A1 | MULTIFUNCTIONAL COPOLYMERS FOR NUCLEIC ACID DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| EP-2081949-A2 | TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | Dharmacon, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| WO-2009015071-A1 | SCREENING OF MICRO-RNA CLUSTER INHIBITOR POOLS | DHARMACON, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| WO-2008036841-A2 | TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | DHARMACON, INC. (US) | 2008-03-27 | — | — | WO | disclosed |